AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 94 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $2,000 | -75.0% | 3,264 | 0.0% | 0.00% | – |
| Q1 2022 | $8,000 | -50.0% | 3,264 | 0.0% | 0.00% | – |
| Q4 2021 | $16,000 | -38.5% | 3,264 | 0.0% | 0.00% | – |
| Q3 2021 | $26,000 | +13.0% | 3,264 | 0.0% | 0.00% | – |
| Q2 2021 | $23,000 | -39.5% | 3,264 | -31.6% | 0.00% | – |
| Q1 2021 | $38,000 | 0.0% | 4,773 | -2.1% | 0.00% | – |
| Q4 2020 | $38,000 | +8.6% | 4,877 | 0.0% | 0.00% | – |
| Q3 2020 | $35,000 | -43.5% | 4,877 | -26.9% | 0.00% | – |
| Q2 2020 | $62,000 | +264.7% | 6,670 | +86.0% | 0.00% | – |
| Q1 2020 | $17,000 | -54.1% | 3,586 | -25.2% | 0.00% | – |
| Q4 2019 | $37,000 | +2.8% | 4,797 | +2.9% | 0.00% | – |
| Q3 2019 | $36,000 | +20.0% | 4,661 | 0.0% | 0.00% | – |
| Q2 2019 | $30,000 | +11.1% | 4,661 | +37.5% | 0.00% | – |
| Q1 2019 | $27,000 | +50.0% | 3,391 | +39.7% | 0.00% | – |
| Q4 2018 | $18,000 | -21.7% | 2,428 | 0.0% | 0.00% | – |
| Q3 2018 | $23,000 | -11.5% | 2,428 | 0.0% | 0.00% | – |
| Q2 2018 | $26,000 | – | 2,428 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $258,000 | 3.49% |
| Aisling Capital Management LP | 1,691,151 | $3,890,000 | 2.10% |
| Sio Capital Management, LLC | 871,101 | $2,004,000 | 0.66% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $6,550,000 | 0.64% |
| Samsara BioCapital, LLC | 883,720 | $2,033,000 | 0.51% |
| Ghost Tree Capital, LLC | 686,599 | $1,579,000 | 0.34% |
| Nantahala Capital Management | 3,200,593 | $7,361,000 | 0.33% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $565,000 | 0.29% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 4,059,894 | $9,338,000 | 0.28% |
| Lion Point Capital, LP | 300,000 | $690,000 | 0.16% |